UDK 616-099-083.98
615.214.2.065
ISSN 2466-2992 (Online) (2022) br.1, p. 31-37
COBISS.SR-ID 75019785
NEUROLEPTIC MALIGNANT SYNDROME IN COVID PANDEMIC – CASE REPORT
Milan Elenkov1, Miloš Milutinović2, Dragan Mitić3, Dušica Janković4, Biljana Stošić5
1General Hospital Pirot, Department of Anesthesiology and Intensive Therapy, 2Special psychiatric hospital „Gornja Toponica“, Niš, 3 General Hospital Pirot, Department od Radiology, , 4Emergency Medicine Service Niš, 5Clinical Centre Niš, Clinic for Anesthesiology and Intensive Therapy
Summary:
Neuroleptic Malignant Syndrome is a very rare but potentially fatal condition that occurs during the use of neuroleptics. It was first described in 1960, followed by a series of reported cases. It is characterized by fever, muscle rigidity, autonomic dysfunction and altered mental status. Although it seems like a very clear entity, the diagnosis itself is not easy to set due to the large number of diseases and conditions that include previous symptoms. There are no definitive guidelines for its treatment. This case report consideres state of malignant neuroleptic syndrome, which was not timely recognized due to curent recommendations that were in place during Covid 19 pandemic. Case report emphasizes the seriousness of the delayed diagnosis and suggests a treatment based on our experience and available literature. Treatment of neuroleptic malignant syndrome is individual and is based on the cessation of neuroleptics or other drugs that caused it, relief of hyperthermia, hydration, thromboprophylaxis, prevention of renal failure and hypostatic changes in the lungs and the introduction of dopamine agonists.
Key words: neuroleptic malignant syndrome, neuroleptics, hyperthermia, rigidity, pharmacotherapy
Correspondence
Milan ELENKOV
Opšta bolnica Pirot
Služba anestezije i intezivne terapije
e-mail: melenkov80@gmail.com
